China's Dalian Fusheng Pharmaceutical Company Co., Ltd. Makes Contribution to Fund Research in Aging and Immunity Sponsored by the Irma and Paul Milstein Program for Senior Health through Milstein Medical Asian American Partnership (MMAAP) Foundation

NEW YORK, Jan. 24, 2018 /PRNewswire/ -- Dalian Fusheng Pharmaceutical Company Co., Ltd, a major pharmaceutical company in Dalian, China has contributed $100,000 to the Milstein Medical Asian American Partnership (MMAAP) Foundation to support research at Johns Hopkins University focusing on aging and immunity. Dr. Li Fu, Chair of Dalian Fusheng Pharmaceutical Company Co., Ltd, signed an MOU with Mr. Howard P. Milstein, Chairman of MMAAP Foundation, to fund work in 2018 sponsored by the MMAAP Foundation's Irma and Paul Milstein Program for Senior Health, with a commitment to contribute another $100,000 to those research efforts in 2019.

Dalian Fusheng Pharmaceutical Company Co., Ltd specializes in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. Focused on innovation, it has extensive experience in producing high quality botanical extracts for dietary supplement, as well as excellent pharmaceutical and nutraceutical products.

The MMAAP Foundation was established in 2011 with a strong endorsement from China's former Ministry of Health (now the National Health and Family Planning Commission). Its mission is to improve world health by facilitating exchanges and long-term partnerships between leading medical institutions and medical talent from the United States and China, as well as greater Asia. The Foundation currently offers funding opportunities for Chinese researchers in Geriatric Medicine, Dermatology, Hematology, Reproductive Medicine and Translational Medicine in the form of fellowships and research project awards. The MMAAP Foundation plans to support other disciplines of research and make funding available to investigators from other regions of Asia in the future.

Dalian Fusheng Pharmaceutical's relationship with the MMAAP Foundation began in 2016 when the company contributed $85,000 to support a MMAAP Foundation Fellowship Award in geriatric medicine under the Irma and Paul Milstein Program for Senior Health.

"Mr. Milstein and MMAAP Foundation have funded many Chinese clinical and medical talents' studies and research. They helped to develop leadership in Chinese medical field, which is exactly what's in need in today's China." said Dr. Fu Li, Chair of Dalian Fusheng Pharmaceutical Company Co., Ltd.

"Enhancing senior health care is crucial for China as well as the rest of the world," said Howard P. Milstein, Chairman of the MMAAP Foundation. "I am appreciative of Dalian Fusheng Pharmaceutical Company's support of our mission. Such a generous contribution will not only help us to facilitate important medical progress in an international setting, but also build trust and collaboration that will benefit future generations."

Dalian Fusheng Pharmaceutical Company Co., Ltd.

Fusheng Pharmaceutical Co., Ltd specializes in ginsenoside Rg3, botanical extracts and Traditional Chinese Medicine. It has extensive experience in producing high quality botanical extracts for dietary supplement, as well as in the pharmaceutical and nutraceutical industries. It is the leading manufacturer of ginsenoside Rg3 in the world. As a science-driven company, it is committed to providing customers with the highest quality products and excellent service.

Milstein Medical Asian American Partnership (MMAAP) Foundation

The mission of the Milstein Medical Asian American Partnership Foundation (MMAAP Foundation) is to improve world health by developing mutually beneficial partnerships between the U.S. and China, as well as greater Asia. Working with some of the premier health organizations in the world, the MMAAP Foundation brings together and funds exchanges between top researchers, medical talent, and medical institutions.

For more than 50 years, the Milstein family has been actively involved in health-related and medical philanthropy, focusing on five areas: Senior Healthcare, Skin Disease and Melanoma, Reproductive Biology, Blood Research, and Translational Medicine. The MMAAP Foundation builds upon this distinguished history, working in close collaboration with other medical organizations supported by the Milstein family, including American Skin Association, the Milstein Melanoma Research Program at the Rockefeller University, the Howard and Georgeanna Jones Foundation for Reproductive Medicine and the Program for Translational Chemical Biology at New York-Presbyterian Hospital/Weill Cornell Medical Center. The MMAAP Foundation is a 501(c) (3) non-profit organization. For more information, please visit the MMAAP Foundation's website: www.mmaapf.org.  

SOURCE Milstein Medical Asian American Partnership Foundation